Cardiovascular diseases represent the greatest burden of global disease. Spending on cardiovascular diseases is higher than for other diseases, with the majority being spent on drugs. Therefore, these drugs and these diseases are hugely important to health systems, society, and pharmaceutical companies. The Health Impact Fund represents a new mechanism by which pharmaceutical innovators would be rewarded on the basis of the health impact of their new drugs. This review illustrates the concept of the Health Impact Fund using the example of novel anticoagulants for prevention of stroke and thromboembolism in atrial fibrillation. By considering existing data and the current situation for novel anticoagulants, we suggest that epidemiologic data and modeling techniques can be used to predict future trends in disease and the health impact of new drugs. The Health Impact Fund may offer potential benefits to pharmaceutical companies, patients, and governments and warrants proper investigation.
Banerjee, Amitava, and Thomas Pogge. “The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?”. Global Heart 9, no. 2 (2014): 255–61. DOI: http://doi.org/10.1016/j.gheart.2014.01.005
Banerjee, A.and T. Pogge. “The Health Impact Fund: How Might It Work for Novel Anticoagulants in Atrial Fibrillation?”. Global Heart, vol. 9, no. 2, 2014, pp. 255–61. DOI: http://doi.org/10.1016/j.gheart.2014.01.005